Stockreport
A $4.8 Billion Reason to Buy BioMarin Stock Today [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
The all-cash transaction values each FOLD share at $14.50, a 33% premium over their previous close, indicating BioMarin's commitment to expanding its footprint in the rare disease market. Chevron Could Raise Its Dividend Next Month - CVX Stock Looks Too Cheap As Google Launches Gemini 3 Flash, Should You Buy, Sell, or Hold GOOGL Stock? Analysts Are Hot on the Foldable iPhone. Should You Buy AAPL Stock Before Apple's Next Big Product Launch? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Despite the recent rally, BioMarin stock is down some 18% versus its year-to-date high set in late March. BMRN shares soared on the Amicus announcement primarily because the acquisition immediately expands its commercial portfolio with two established treatments, Galafold and Pombiliti-Opfolda. Both of those therapies address lysosomal storage disord
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $100.00. They now have a "buy" rating on the stock.[MarketBeat]
- BioMarin: Amicus Buyout Sparks My Enthusiasm [Seeking Alpha][Seeking Alpha]
- BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B [Yahoo! Finance][Yahoo! Finance]
- BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target raised by analysts at HC Wainwright from $55.00 to $60.00. They now have a "neutral" rating on the stock.[MarketBeat]
- More
BMRN
SEC Filings
SEC Filings
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- 12/17/25 - Form 8-K
- BMRN's page on the SEC website
- More